• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Atherosclerosis Partnering 2010-2015 Product Image

Atherosclerosis Partnering 2010-2015

  • ID: 2074742
  • March 2015
  • Region: Global
  • 100 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Atherosclerosis Partnering 2010-2015 report provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in atherosclerosis partnering deals
Top atherosclerosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Atherosclerosis Partnering 2010-2015 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of atherosclerosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors atherosclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in atherosclerosis partnering

2.1. Introduction
2.2. Atherosclerosis partnering over the years
2.3. Atherosclerosis partnering by deal type
2.4. Atherosclerosis partnering industry sector
2.5. Atherosclerosis partnering by stage of development
2.6. Atherosclerosis partnering by technology type

Chapter 3 – Average deal terms for atherosclerosis

3.1 Introduction
3.2 Average deal terms for atherosclerosis
3.3 Atherosclerosis headline values with median calculation
3.4 Atherosclerosis upfront values with median calculation
3.5 Atherosclerosis milestone values with median calculation
3.6 Atherosclerosis royalty rates with median calculation

Chapter 4 – Active atherosclerosis dealmakers

4.1. Introduction
4.2 Most active atherosclerosis dealmakers
4.3. Top atherosclerosis deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 – Atherosclerosis dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 – Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products

Table of figures

Figure 1: Atherosclerosis partnering since 2010
Figure 2: Atherosclerosis dealmaking activity– 2010 to 2015
Figure 3: Atherosclerosis partnering by deal type since 2010
Figure 4: Atherosclerosis partnering by industry sector since 2010
Figure 5: Atherosclerosis partnering by stage of development since 2010
Figure 6: Atherosclerosis partnering by technology type since 2010
Figure 7: Atherosclerosis deals with a headline value
Figure 8: Atherosclerosis deals with upfront payment values
Figure 9: Atherosclerosis deals with milestone payments
Figure 10: Atherosclerosis deals with royalty rates, %
Figure 11: Top atherosclerosis deals by value since 2010
Figure 12: Big pharma – top 50 – atherosclerosis deals 2010 to 2015
Figure 13: Big pharma atherosclerosis deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – atherosclerosis deals 2010 to 2015
Figure 15: Big biotech atherosclerosis deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

Note: Product cover images may vary from those shown

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

AB Sciex Eli Lilly and Company B. Braun Melsungen AG Astellas Pharma, Inc. Hologic Corporation Merck & Co., Inc.